U.K. Offers $13.4 Million To India For Cheap AIDS, Malaria Drugs
This article was originally published in PharmAsia News
Executive Summary
The United Kingdom is offering more than $13.4 million to fund Indian drug makers that make lower-cost drug to fight AIDS and malaria. The program is set to begin next year and last through 2012 to provide technical support to firms that carry drugs through the registration stage and are willing to negotiate prices for them. The program is estimated to have a potential to help more than 11 million people gain access to treatment during the period. The U.K. government is working with the Clinton Foundation to help Indian drug makers make cheaper drugs for the diseases. (Click here for more
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.